Identify the design before comparing results
Separate observational work, case material, uncontrolled reports, and prospective studies. Study type affects what can reasonably be inferred about outcomes, adverse events, and applicability.
Evidence desk / 06
Research Resources
A practical library for people researching Iboverse: study records, published summaries, regulatory materials, and the questions that keep evidence in proportion.
This page is organized for investigators, regulators, and readers who need to distinguish primary sources from interpretation without turning research material into operational advice.
Evidence should retain its setting, methods, and limits.
Starting point
Read the record, not the headline.
Research on ibogaine spans different study designs, settings, and populations. A usable library keeps peer-reviewed papers, trial registry entries, review articles, datasets, and regulator publications visibly distinct so that a preliminary finding is not mistaken for settled evidence.
For a broader orientation to evidence, safety, legality, and practical questions, the Iboverse overview of the research landscape provides context before individual studies are compared. For readers looking at care settings rather than research records, questions to ask when assessing ibogaine therapy options can help frame practical due diligence without treating a directory as proof of safety or quality.
01 / Study map
Build from primary records.
Start with the publication or registry entry itself. Capture the research question, design, sample, setting, outcomes, follow-up period, funding disclosures, and reported limitations before using a summary.
Keep registrations alongside publications
The ClinicalTrials.gov study registry can show stated outcomes, eligibility criteria, recruitment status, and changes that may not be clear from a later publication alone.
Use synthesis carefully
Systematic reviews and meta-analyses can organize a field, but their conclusions depend on the studies included and the comparability of methods. Record whether underlying data or a protocol is available, and note where it is not.
02 / Documentation
Safety materials need their own evidence trail.
Published studies may describe screening, informed consent, cardiac observation, neurocognitive assessment, exclusions, and adverse-event reporting. These materials are useful for understanding what investigators documented; they are not a substitute for medical judgment or a protocol for unregulated use.
- 01 Provenance. Identify whether a document comes from a published method, a registry record, a regulator, or an unverified secondary source.
- 02 Population and exclusions. Note who was included, who was excluded, and why those boundaries matter to interpretation.
- 03 Event reporting. Look for how adverse events were defined, monitored, recorded, and followed up.
03 / Regulatory context
Jurisdiction changes the meaning of a source.
“A study record can describe investigation without establishing authorization, availability, or a standard of care.”
Regulatory snapshots should be read in the relevant jurisdiction and dated. In the United States, the FDA’s information on investigational new drug applications explains the framework used to support clinical investigation. In the European Union, the European Medicines Agency’s clinical trials overview provides a separate regulatory reference point.
For terminology and historical context, the overview of ibogaine’s research and legal history is a starting reference, not a substitute for current national guidance. Readers comparing public information with service claims can also consult the site’s practical review of research-oriented questions to keep the distinction between information and clinical care clear.
04 / Interpretation
Questions for a more careful reading.
These prompts are designed to surface uncertainty, not hide it. They are especially useful where public summaries compress complex methods into a single claim.
What belongs in a research bibliography?
A useful bibliography distinguishes peer-reviewed reports, registry records, reviews, datasets, and regulatory material. Each entry should be annotated with publication status, study design, setting, population, and limitations rather than presented as interchangeable evidence.
Why keep safety material separate from efficacy claims?
Safety questions involve different evidence: screening criteria, exclusions, observation methods, adverse-event definitions, reporting practices, and follow-up. Outcomes alone cannot establish that these questions were adequately addressed.
How should ethical questions enter trial design review?
Review participant selection, the clarity of informed consent, the handling of treatment tourism, independent oversight, the plan for adverse-event reporting, and whether limits of the study are plainly communicated. Ethical review is part of interpreting the quality of a record, not an optional appendix.
Can these resources be used as medical or legal advice?
No. This library is for research and practical context. It does not provide operational instructions for unregulated use, and it is not medical or legal advice. The cardiac safety evidence page further separates published safety concerns from individualized medical decisions.
Keep the limits visible.
A good research library does more than collect links. It preserves source provenance, makes uncertainty legible, and helps people researching Iboverse ask whether a claim travels beyond the evidence supporting it.
Continue to the evidence review